The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
Open accessAbstract
Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an anti-viral agent that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRp) of RNA viruses. Favipiravir was discovered through screening chemical library for anti-viral activity against the influenza virus by Toyama Chemical Co., Ltd. Favipiravir undergoes an intracellular phosphoribosylation to be an active form, favipiravir-RTP (favipiravir ribofuranosyl-5'-triphosphate), which is recognized as a substrate by RdRp, and inhibits the RNA polymerase activity. Since the catalytic domain of RdRp is conserved among various types of RNA viruses, this mechanism of action underpins a broader spectrum of anti-viral activities of favipiravir. Favipiravir is effective against a wide range of types and subtypes of influenza viruses, including strains resistant to existing anti-influenza drugs. Of note is that favipiravir shows anti-viral activities against other RNA viruses such as arenaviruses, bunyaviruses and filoviruses, all of which are known to cause fatal hemorrhagic fever. These unique anti-viral profiles will make favipiravir a potentially promising drug for specifically untreatable RNA viral infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fever with Thrombocytopenia Associated with a Novel Bunyavirus in China
Yu, X.-J., Liang, M.-F., Zhang, S.-Y., Liu, Y., Li, J.-D., Sun, Y.-L., Zhang, L., Zhang, Q.-F., Popov, V. L., Li, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010095 · Cited by 1,941
Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections
WHO Ebola Response Team (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411100 · Cited by 1,674
In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses
Itoh, Y., Shinya, K., Kiso, M., Watanabe, T., Sakoda, Y., Hatta, M., Muramoto, Y., Tamura, D., Sakai-Tagawa, Y., Noda, T., et al. (2009) · Nature · doi:10.1038/nature08260 · Cited by 1,073
Self-citationFavipiravir (T-705), a novel viral RNA polymerase inhibitor
Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., & Barnard, D. L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.015 · Cited by 1,072
Self-citationClinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus Infection
(2010) · New England Journal of Medicine · doi:10.1056/nejmra1000449 · Cited by 1,062
McCormick, J. B., King, I. J., Webb, P. A., Scribner, C. L., Craven, R. B., Johnson, K. M., Elliott, L. H., & Belmont-Williams, R. (1986) · New England Journal of Medicine · doi:10.1056/nejm198601023140104 · Cited by 999
Takahashi, T., Maeda, K., Suzuki, T., Ishido, A., Shigeoka, T., Tominaga, T., Kamei, T., Honda, M., Ninomiya, D., Sakai, T., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit603 · Cited by 958
Severe Fever with Thrombocytopenia Syndrome, South Korea, 2012
Kim, K.-H., Yi, J., Kim, G., Choi, S. J., Jun, K. I., Kim, N.-H., Choe, P. G., Kim, N.-J., Lee, J.-K., & Oh, M.-D. (2013) · Emerging Infectious Diseases · doi:10.3201/eid1911.130792 · Cited by 702
Epidemiology of Human Infections with Avian Influenza A(H7N9) Virus in China
Li, Q., Zhou, L., Zhou, M., Chen, Z., Li, F., Wu, H., Xiang, N., Chen, E., Tang, F., Wang, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304617 · Cited by 688
Mechanism of Action of T-705 against Influenza Virus
Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., Nomura, N., Egawa, H., & Shiraki, K. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.981-986.2005 · Cited by 546
Self-citationIn Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705
Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.977-981.2002 · Cited by 501
Self-citationOestereich, L., Lüdtke, A., Wurr, S., Rieger, T., Muñoz-Fontela, C., & Günther, S. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.02.014 · Cited by 493
Sheu, T. G., Deyde, V. M., Okomo-Adhiambo, M., Garten, R. J., Xu, X., Bright, R. A., Butler, E. N., Wallis, T. R., Klimov, A. I., & Gubareva, L. V. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00555-08 · Cited by 480
Streeter, D. G., Witkowski, J. T., Khare, G. P., Sidwell, R. W., Bauer, R. J., Robins, R. K., & Simon, L. N. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.4.1174 · Cited by 478
Sissoko, D., Laouenan, C., Folkesson, E., M’Lebing, A.-B., Beavogui, A.-H., Baize, S., Camara, A.-M., Maes, P., Shepherd, S., Danel, C., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001967 · Cited by 478
T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections
Furuta, Y., Takahashi, K., Shiraki, K., Sakamoto, K., Smee, D. F., Barnard, D. L., Gowen, B. B., Julander, J. G., & Morrey, J. D. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.02.198 · Cited by 471
Self-citationCharacterization of H7N9 influenza A viruses isolated from humans
Watanabe, T., Kiso, M., Fukuyama, S., Nakajima, N., Imai, M., Yamada, S., Murakami, S., Yamayoshi, S., Iwatsuki-Horimoto, K., Sakoda, Y., et al. (2013) · Nature · doi:10.1038/nature12392 · Cited by 399
Zmurko, J., Marques, R. E., Schols, D., Verbeken, E., Kaptein, S. J. F., & Neyts, J. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004695 · Cited by 292
Jin, Z., Smith, L. K., Rajwanshi, V. K., Kim, B., & Deval, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068347 · Cited by 268
Ribavirin's antiviral mechanism of action: lethal mutagenesis?
Crotty, S., Cameron, C., & Andino, R. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-001-0308-0 · Cited by 248
Delang, L., Segura Guerrero, N., Tas, A., Quérat, G., Pastorino, B., Froeyen, M., Dallmeier, K., Jochmans, D., Herdewijn, P., Bello, F., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku209 · Cited by 232
Smither, S. J., Eastaugh, L. S., Steward, J. A., Nelson, M., Lenk, R. P., & Lever, M. S. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.01.012 · Cited by 228
T-705 (favipiravir) activity against lethal H5N1 influenza A viruses
Kiso, M., Takahashi, K., Sakai-Tagawa, Y., Shinya, K., Sakabe, S., Le, Q. M., Ozawa, M., Furuta, Y., & Kawaoka, Y. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909603107 · Cited by 207
Self-citationOestereich, L., Rieger, T., Neumann, M., Bernreuther, C., Lehmann, M., Krasemann, S., Wurr, S., Emmerich, P., de Lamballerie, X., Ölschläger, S., et al. (2014) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0002804 · Cited by 182
Tani, H., Fukuma, A., Fukushi, S., Taniguchi, S., Yoshikawa, T., Iwata-Yoshikawa, N., Sato, Y., Suzuki, T., Nagata, N., Hasegawa, H., et al. (2016) · mSphere · doi:10.1128/msphere.00061-15 · Cited by 170
Mapping the zoonotic niche of Lassa fever in Africa
Mylne, A. Q. N., Pigott, D. M., Longbottom, J., Shearer, F., Duda, K. A., Messina, J. P., Weiss, D. J., Moyes, C. L., Golding, N., & Hay, S. I. (2015) · Transactions of The Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/trv047 · Cited by 168
Efficacy of Orally Administered T-705 on Lethal Avian Influenza A (H5N1) Virus Infections in Mice
Sidwell, R. W., Barnard, D. L., Day, C. W., Smee, D. F., Bailey, K. W., Wong, M., Morrey, J. D., & Furuta, Y. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01051-06 · Cited by 161
Self-citationBai, C., Mu, J., Kargbo, D., Song, Y., Niu, W., Nie, W., Kanu, A., Liu, W., Wang, Y., Dafae, F. M., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw571 · Cited by 153
Favipiravir elicits antiviral mutagenesis during virus replication in vivo
Arias, A., Thorne, L., & Goodfellow, I. (2014) · eLife · doi:10.7554/elife.03679 · Cited by 150
Favipiravir: A New Medication for the Ebola Virus Disease Pandemic
Nagata, T., Lefor, A. K., Hasegawa, M., et al. (2014) · Disaster Medicine and Public Health Preparedness · doi:10.1017/dmp.2014.151 · Cited by 141
Safronetz, D., Rosenke, K., Westover, J. B., Martellaro, C., Okumura, A., Furuta, Y., Geisbert, J. B., Saturday, G. A., Komeno, T., Geisbert, T. W., et al. (2015) · Scientific Reports · doi:10.1038/srep14775 · Cited by 141
Self-citationScharton, D., Bailey, K. W., Vest, Z. G., Westover, J. B., Kumaki, Y., Wettere, A. J. V., Furuta, Y., & Gowen, B. B. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.01.016 · Cited by 111
Self-citationMendenhall, M., Russell, A., Smee, D. F., Hall, J. O., Skirpstunas, R. T., Furuta, Y., & Gowen, B. B. (2011) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001342 · Cited by 108
Self-citationVanderlinden, E., Vrancken, B., Houdt, J. V., Rajwanshi, V. K., Gillemot, S., Andreï, G., Lemey, P., & Naesens, L. M. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01156-16 · Cited by 108
In Vitroandin VivoActivities of T-705 and Oseltamivir against Influenza Virus
Takahashi, K., Furuta, Y., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., & Shiraki, K. (2003) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020301400502 · Cited by 90
Self-citationLethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
de Ávila, A. I., Gallego, I., Soria, M. E., Gregori, J., Quer, J., Esteban, J. I., Rice, C. M., Domingo, E., & Perales, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164691 · Cited by 74
Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models
Gowen, B. B., Wong, M., Jung, K., Smee, D. F., Morrey, J. D., & Furuta, Y. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.015 · Cited by 71
Self-citationJin, Z., Tucker, K., Lin, X., Kao, C. C., Shaw, K., Tan, H. T., Symons, J. A., Behera, I., Rajwanshi, V. K., Dyatkina, N. B., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01391-15 · Cited by 67
In Vitro Assessment of Combinations of Enterovirus Inhibitors against Enterovirus 71
Wang, Y., Li, G., Yuan, S., Gao, Q., Lan, K., Altmeyer, R. M., & Zou, G. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01073-16 · Cited by 49
Maporal Virus as a Surrogate for Pathogenic New World Hantaviruses and its Inhibition by Favipiravir
Buys, K. K., Jung, K., Smee, D. F., Furuta, Y., & Gowen, B. B. (2011) · Antiviral chemistry & chemotherapy · doi:10.3851/imp1729 · Cited by 45
Self-citationShrimpton, R., & Mason, J. O. (2012) · Pathogens and Global Health · doi:10.1179/2047772412z.00000000059 · Cited by 1
Cited by
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020) · JAMA · doi:10.1001/jama.2020.6019 · Cited by 2,347
COVID-19 and cardiovascular disease
Clerkin, K. J., Fried, J. A., Raikhelkar, J., Sayer, G., Griffin, J. M., Masoumi, A., Jain, S. S., Burkhoff, D., Kumaraiah, D., Rabbani, L., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046941 · Cited by 1,738
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Dong, L., Hu, S., & Gao, J. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.01012 · Cited by 1,390
Gordon, C. J., Tchesnokov, E. P., Woolner, E., Perry, J. K., Feng, J. Y., Porter, D. P., & Götte, M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013679 · Cited by 985
SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development
Wang, M.-Y., Zhao, R., Gao, L.-J., Gao, X.-F., Wang, D.-P., & Cao, J.-M. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.587269 · Cited by 874
Metadata
- Authors
- FURUTA, Y., KOMENO, T., & NAKAMURA, T.
- Venue
- Proceedings of the Japan Academy, Series B
- Publisher
- Japan Academy
- Published
- 2017
- Volume
- 93
- Issue
- 7
- Pages
- 449-463
- ISSN
- 0386-2208 (ISSN-L)
- 1349-2896
- OpenAlex
- W2739679816
- Cited by
- 1,070
- References
- 41
- FWCI
- 69.19
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.